Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

Atypical (second-generation) antipsychotic

Aripiprazole (Long-Acting Injection)

Abilify Maintena (monthly) and Abilify Asimtufii (every 2 months) — Otsuka Pharmaceutical / Lundbeck Canada

Dosage form
Injection
Available strengths
Maintena: 300 mg or 400 mg vial/syringe, monthly; Asimtufii: 720 mg/2.4 mL or 960 mg/3.2 mL syringe, every 2 months
Drug class
Atypical (second-generation) antipsychotic
Common brand
Abilify Maintena (monthly) and Abilify Asimtufii (every 2 months) — Otsuka Pharmaceutical / Lundbeck Canada

Indication

Common therapeutic uses

  • Treatment of schizophrenia in adult patients — both Maintena (monthly) and Asimtufii (every two months) are indicated, with efficacy established in acute and maintenance phases.
  • Maintenance monotherapy treatment of bipolar I disorder in adult patients — both products share this indication.
  • Asimtufii's efficacy and safety are based on the clinical trials that established Abilify Maintena's efficacy and safety, plus pharmacokinetic bridging data: in a randomized, parallel-arm study, Asimtufii 960 mg given once every two months was shown to provide similar aripiprazole concentrations to Maintena 400 mg given monthly over the dosing interval — Asimtufii itself was not separately proven in fresh efficacy trials.

Pregnancy

Risk assessment and monitoring considerations

  • There are no adequate and well-controlled studies of aripiprazole in pregnant women; it is not known whether aripiprazole can cause fetal harm or affect reproductive capacity, and animal studies showed developmental toxicity including possible teratogenic effects in rats and rabbits.
  • Neonates exposed to antipsychotics, including aripiprazole, during the third trimester are at risk of extrapyramidal and/or withdrawal symptoms after delivery — agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder have been reported, ranging from self-limited to requiring neonatal ICU support and prolonged hospitalization.
  • Neither product should be used during pregnancy unless expected maternal benefit clearly outweighs fetal risk; because both are long-acting injections, prescribers must factor in that aripiprazole plasma concentrations persist for weeks to months after the last dose (Asimtufii: aripiprazole has been detected in plasma up to 34 weeks after a single injection), so the drug cannot simply be "stopped" at the moment pregnancy is discovered the way an oral dose can.

Breastfeeding

Infant exposure considerations

  • Aripiprazole is excreted in human breast milk; a decision must be made whether to discontinue breastfeeding or to discontinue/abstain from Maintena or Asimtufii therapy, weighing the benefit of breastfeeding to the infant against the benefit of continued treatment to the mother.
  • Because the long-acting injections persist in the body for weeks to months, this benefit/risk decision cannot be resolved simply by a short treatment pause the way it might be with a same-day-cleared oral drug.

Geriatrics

Dosing and tolerability considerations

  • Both products carry a Serious Warnings and Precautions Box: elderly patients with dementia treated with atypical antipsychotic drugs are at increased risk of death compared with placebo — a meta-analysis of 13 placebo-controlled trials of various atypical antipsychotics showed a mean 1.6-fold increase in death rate; in three placebo-controlled aripiprazole trials in elderly Alzheimer's-disease patients (n=938, mean age 82.4 years), death occurred in 3.5% of aripiprazole-treated patients versus 1.7% on placebo, with deaths mostly cardiovascular (heart failure, sudden death) or infectious (pneumonia) in nature.
  • Neither Maintena nor Asimtufii is approved/indicated for treating dementia-related psychosis in elderly patients.
  • Elderly patients with dementia treated with oral aripiprazole in placebo-controlled trials also showed increased cerebrovascular adverse events (stroke, transient ischemic attack), including fatalities, with a statistically significant dose-response relationship in one fixed-dose study.
  • Safety and efficacy of either LAI in patients 65 years or older have not been formally established; no dosage adjustment is recommended based on age alone, but a lower starting dose should be considered when clinical factors warrant, and geriatric patients need closer monitoring during initial dosing given generally reduced cardiac, hepatic, and renal function plus more concomitant medications. Dysphagia (esophageal dysmotility/aspiration) is a specific added risk in elderly dementia patients.

Pediatrics

Use in children and adolescents

  • Safety and efficacy of Abilify Maintena have not been evaluated in patients under 18 years of age and its use is not recommended.
  • No data are available to Health Canada for Abilify Asimtufii in patients under 18 years of age; Health Canada has not authorized a pediatric indication for Asimtufii.

Dosage & Administration

Practical dosing and administration

  • Tolerability screening (both products): for any patient who has never taken aripiprazole — including patients switching from another oral antipsychotic — tolerability with oral aripiprazole must be established before starting either long-acting injection; titration of the injectable dose itself is not required for either product once tolerability is confirmed.
  • Maintena — starting/maintenance dose: 400 mg by intramuscular injection into the deltoid or gluteal muscle, administered by a healthcare professional once monthly as a single injection, no sooner than 26 days after the previous injection. If adverse reactions occur at 400 mg, dose reduction to 300 mg once monthly should be considered.
  • Maintena — the 14-day oral overlap rule: after the FIRST Maintena injection, treatment must continue with oral aripiprazole 10–20 mg for 14 consecutive days to maintain therapeutic antipsychotic concentrations while the depot slowly reaches steady state; this applies both to patients newly starting aripiprazole and to patients switching from a different oral antipsychotic (who continue their current oral antipsychotic, not aripiprazole, for the same 14 days). This 14-day overlap is only required around treatment initiation, not around every subsequent monthly injection.
  • Asimtufii — maintenance dose: 960 mg by deep intramuscular gluteal injection ONLY (never deltoid) as a single injection every two months (no sooner than 56 days after the previous injection); may be given up to 1 week before or 1 week after the two-month scheduled timepoint. If adverse reactions occur at 960 mg, reduce to 720 mg once every two months, or switch to Maintena 300 mg once monthly.
  • Asimtufii — three permitted initiation regimens, each still requiring tolerability with oral aripiprazole first: (1) One-injection start — give one Asimtufii 960 mg injection and continue the current oral aripiprazole (10–20 mg) or current oral antipsychotic for 14 days, then dose Asimtufii every 2 months thereafter. (2) Two-injection start — discontinue the current oral antipsychotic, then on the same day give one Asimtufii 960 mg injection AND one Maintena 400 mg injection at separate injection sites plus a single 20 mg oral aripiprazole dose (no further oral overlap needed). (3) Transition from Maintena — give one Asimtufii 960 mg injection in place of the next scheduled Maintena injection (no sooner than 26 days after the last Maintena dose); this may replace the second or any later Maintena injection, and needs no additional oral aripiprazole.
  • Manufacturer training materials on dosing/administration for both products are available to healthcare professionals via www.AbilifyAsimtufii.ca or by calling 1-877-341-9245.
  • Reconstitution — Maintena dual-chamber syringe: push the plunger to release the diluent chamber into the powder chamber, then shake vigorously for 20 seconds until uniformly milky-white; inspect for particulate matter/discoloration before injecting; inject immediately after reconstitution.
  • Reconstitution — Maintena vial: reconstitute at room temperature using ONLY the Sterile Water for Injection supplied in the kit — 1.9 mL for the 400 mg vial, 1.5 mL for the 300 mg vial (note there is more diluent in the water vial than is actually needed, so the full vial volume is not used); withdraw the correct volume with the supplied 3 mL syringe/21-gauge needle, inject it into the powder vial, and use the vial adapter to draw up the reconstituted suspension for injection.
  • Needle selection — Maintena: for deltoid injection use a 23-gauge, 1-inch (25 mm) needle in non-obese patients or a 22-gauge, 1.5-inch (38 mm) needle in obese patients; for gluteal injection use a 22-gauge, 1.5-inch (38 mm) needle in non-obese patients or a 21-gauge, 2-inch (51 mm) needle in obese patients. Injection sites should be rotated between the two deltoid or gluteal muscles month to month.
  • Needle selection — Asimtufii (gluteal only): a 22-gauge, 1.5-inch (38 mm) black-hub needle for patients without obesity, or a 21-gauge, 2-inch (51 mm) green-hub needle for patients with obesity; the kit supplies both needles so the correct one can be chosen by body type at the time of injection. Before injecting, tap the syringe on the hand at least 10 times and then shake vigorously for at least 10 seconds until uniform.
  • Both products are for deep intramuscular injection ONLY — never intravenous or subcutaneous — and each pre-filled syringe/vial is single-use; do not massage the injection site after administration.
  • Maintena missed-dose rule (2nd or 3rd dose): if 4 to under 5 weeks have elapsed since the last injection, give the injection as soon as possible and resume the monthly schedule; if 5 or more weeks have elapsed, restart oral aripiprazole for 14 days alongside the next injection.
  • Maintena missed-dose rule (4th or later dose): if 4 to under 6 weeks have elapsed, give as soon as possible and resume monthly dosing; if 6 or more weeks have elapsed, restart oral aripiprazole for 14 days alongside the next injection.
  • Asimtufii missed-dose rules are date-of-injection–specific and steady state (reached by the 4th consecutive injection) matters: before steady state, if the 2nd dose is missed and under 12 weeks have passed since the 1st injection (or the 3rd dose is missed with under 14 weeks since the 2nd), give the next dose as soon as possible and resume the 2-month schedule; if the delay is longer than those windows, either restart oral aripiprazole for 14 days with the next Asimtufii injection, OR give two separate injections (one Asimtufii plus one Maintena 400 mg) together with a single 20 mg oral aripiprazole dose. After steady state, the same two options apply if 16 or more weeks (8+ week delay) have elapsed since the last injection; under 16 weeks, simply resume on schedule.
  • CYP2D6/CYP3A4 dose-adjustment table — Maintena: known CYP2D6 poor metabolizers should receive 300 mg (or 200 mg if also on a strong CYP3A4 inhibitor); patients on 400 mg who add a strong CYP2D6 OR strong CYP3A4 inhibitor should reduce to 300 mg (200 mg if both); patients on 300 mg who add a strong inhibitor of either enzyme should reduce to 200 mg (160 mg if both); concomitant CYP3A4 inducers for more than 14 days should be avoided; if an inhibitor/inducer is later withdrawn, the Maintena dose may need to be increased back to the prior dose.
  • CYP2D6/CYP3A4 dose-adjustment table — Asimtufii (materially different from Maintena): Asimtufii is CONTRAINDICATED in known CYP2D6 poor metabolizers (this is a hard contraindication, not a dose reduction, as of the 2025-08 label — a genuine difference from Maintena, where poor metabolizers are simply dosed lower). In CYP2D6 poor metabolizers who are also on a strong CYP3A4 inhibitor, Asimtufii should be avoided entirely. In patients who are extensive metabolizers on the 960 mg maintenance dose, adding a strong CYP2D6 inhibitor should be avoided; adding a strong CYP3A4 inhibitor calls for reducing to 720 mg (increase back to 960 mg if the inhibitor is stopped); CYP3A4 inducers should be avoided with Asimtufii.
  • Renal impairment: no dosage adjustment is required for either product. Hepatic impairment: no adjustment needed for mild-to-moderate impairment for either product; data are insufficient for severe hepatic impairment, so dosing should be managed cautiously and oral aripiprazole considered instead. No dosage adjustment is recommended for either product based on gender, race, or smoking status.
  • If either Maintena or Asimtufii is discontinued, its prolonged-release characteristics must be factored into clinical decisions, since aripiprazole continues to be released and absorbed for weeks after the last injection.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • No cases of overdose have been reported in pre-marketing or clinical studies with either Maintena or Asimtufii; because both are administered exclusively by a healthcare professional, the potential for patient-initiated overdose is low, and suicide via overdose is considered unlikely.
  • Reference data instead comes from oral aripiprazole overdose: a single post-marketing death was possibly associated with acute overdose of 900 mg of aripiprazole alone (patient had a history of excessive alcohol use, was in intensive care for 10–14 days, and died); the largest confirmed nonfatal oral ingestion on record was 1680 mg, with only vomiting, fatigue, and dizziness reported. A nonfatal accidental pediatric ingestion of up to 195 mg in a 2.5-year-old caused vomiting, somnolence, lethargy, transient loss of consciousness, and CNS depression.
  • Commonly reported oral-overdose adverse reactions (≥5% of overdose cases) are vomiting, somnolence, and tremor; other reported signs/symptoms include acidosis, aggression, elevated liver enzymes, atrial fibrillation, bradycardia, coma, confusion, seizures, elevated creatine phosphokinase, hypertension, hypokalemia, hypotension, loss of consciousness, QRS/QT prolongation, aspiration pneumonia, respiratory arrest, status epilepticus, and tachycardia.
  • Management is supportive: maintain airway, oxygenation, and ventilation; start continuous cardiac/ECG monitoring immediately given the possibility of multi-drug involvement; continue close medical supervision until recovery. There is no specific antidote to aripiprazole, and because of the prolonged-release depot's half-life, clinicians must factor in an extended recovery/monitoring timeline compared with an oral overdose. Contact a regional poison control centre or Health Canada's 1-844-POISON-X (1-844-764-7669) line for current overdose management guidance.

Common side effects

Frequently reported tolerability concerns

  • Maintena (schizophrenia maintenance trials, ≥5% incidence): insomnia (10.9%), weight increased (9.4%), akathisia (8.1%), headache (7.9%), anxiety (6.6%), weight decreased (6.6%), nasopharyngitis (5.8%), and injection site pain (5.2%).
  • Maintena (acute schizophrenia trial, ≥5% and at least double the placebo rate): weight increased, akathisia, sedation, and injection site pain.
  • Maintena (bipolar I disorder trial, ≥5% and greater than placebo): weight increased, akathisia, anxiety, restlessness, and somnolence.
  • Asimtufii (32-week open-label study, ≥5% incidence): weight increased, injection site pain, akathisia, anxiety, headache, insomnia, and constipation — injection site pain and headache were reported about twice as frequently with Asimtufii as with Maintena, likely reflecting its larger injection volume and gluteal-only administration.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Increased mortality and cerebrovascular events (stroke, transient ischemic attack) in elderly patients with dementia-related psychosis — see Geriatrics; this is the boxed Serious Warnings and Precautions content for both products.
  • Neuroleptic malignant syndrome (NMS) — a potentially fatal symptom complex presenting as hyperpyrexia, muscle rigidity, altered mental status, and autonomic instability (irregular pulse/blood pressure, tachycardia, diaphoresis, cardiac dysrhythmia), sometimes with elevated CPK, myoglobinuria/rhabdomyolysis, and acute renal failure; management requires immediate discontinuation of all antipsychotics, intensive supportive treatment, and monitoring, since there is no agreed-upon specific pharmacologic treatment.
  • Tardive dyskinesia — a syndrome of potentially irreversible, involuntary dyskinetic movements that can develop even after relatively brief, low-dose treatment; risk and irreversibility increase with cumulative dose and duration; there is no known treatment for established cases, so both products should be prescribed at the lowest effective dose for the shortest necessary duration.
  • Severe cutaneous adverse reactions (SCARs) — Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis have all been reported with atypical antipsychotic exposure, including aripiprazole; discontinue the drug if these occur. DRESS specifically has been reported post-market with the Abilify formulations.
  • Severe neutropenia/agranulocytosis — discontinue the drug if absolute neutrophil count falls below 1×10⁹/L, and monitor CBC closely in patients with a history of low white cell counts or drug-induced leukopenia/neutropenia.
  • Venous thromboembolism, including fatal pulmonary embolism, has been reported with antipsychotic drugs including aripiprazole; assess and address VTE risk factors before and during treatment.
  • Seizures/convulsions — use cautiously in patients with a seizure history or conditions that lower seizure threshold (more prevalent in patients over 65).
  • Dysphagia (esophageal dysmotility and aspiration) — a recognized risk of antipsychotic use, particularly in elderly patients with advanced dementia, where aspiration pneumonia is a leading cause of morbidity and mortality.
  • Hepatic failure has been reported post-market at an unknown frequency, alongside very rare hepatitis and jaundice; post-market cases of suicide attempt, suicidal ideation, and completed suicide have also been reported despite the drug being clinician-administered.

Use with caution

Situations requiring closer assessment

  • Impulse-control disorders — a risk relatively distinctive to aripiprazole among antipsychotics, linked to its partial dopamine-agonist activity: post-marketing reports describe pathological gambling in patients treated with aripiprazole, with patients experiencing increased urges (particularly to gamble) and an inability to control them. Patients with a prior history of a gambling disorder may be at increased risk and should be monitored carefully. Other urges reported very rarely include increased sexual urges (hypersexuality), compulsive spending, and binge or compulsive eating, plus other impulsive/compulsive behaviours. Because patients often do not recognize these behaviours as abnormal, prescribers are specifically instructed to ask patients or caregivers about new or increased gambling, sexual, spending, or eating urges. In some (not all) cases, urges stopped when the dose was reduced or the medication discontinued; dose reduction or discontinuation should be considered if such urges develop.
  • Orthostatic hypotension — aripiprazole's α1-adrenergic antagonism can cause orthostatic hypotension, tachycardia, dizziness, and sometimes syncope, especially at treatment initiation; use with caution in patients with known cardiovascular disease (prior MI, ischemic heart disease, heart failure, conduction abnormalities), cerebrovascular disease, or conditions predisposing to hypotension (dehydration, hypovolemia, antihypertensive treatment); monitor orthostatic vital signs in vulnerable patients.
  • QT prolongation — reported very rarely in post-marketing experience; use cautiously in patients with congenital or acquired long QT syndrome, a family history of QT prolongation, or electrolyte disturbances (hypokalemia, hypomagnesemia, hypocalcemia) that predispose to arrhythmia.
  • Hyperglycemia and diabetes mellitus — exacerbation of pre-existing diabetes, new hyperglycemia, and (very rarely) diabetic ketoacidosis or diabetic coma, including fatal cases, have been reported with oral aripiprazole; obtain baseline and periodic blood glucose and weight monitoring, and test fasting glucose in patients who develop hyperglycemia symptoms (polydipsia, polyuria, polyphagia, weakness).
  • Dyslipidemia and weight gain — both are recognized metabolic changes associated with atypical antipsychotics; periodic monitoring of lipids and weight is recommended.
  • Priapism — rare cases have been reported with antipsychotic use including oral aripiprazole; the reaction is not clearly dose-dependent or duration-related.
  • Falls — antipsychotics including aripiprazole can cause somnolence, postural hypotension, and motor/sensory instability that increase fall risk; complete fall-risk assessments at initiation and periodically during long-term therapy.
  • Body temperature regulation — antipsychotics can impair the body's ability to reduce core temperature; use appropriate care in patients who will be exercising strenuously, exposed to extreme heat, on concomitant anticholinergic medication, or at risk of dehydration.
  • Cognitive/motor impairment — instruct patients not to drive or operate hazardous machinery until they know the drug does not affect them adversely, given potential effects on judgment, thinking, and motor skills.

Contraindications

Situations where therapy may be inappropriate

  • Both Maintena and Asimtufii are contraindicated in patients hypersensitive to aripiprazole or to any non-medicinal ingredient in the formulation, or to any component of the syringe/vial/container.
  • Asimtufii carries an ADDITIONAL contraindication not present for Maintena: it is contraindicated in patients who are known CYP2D6 poor metabolizers (added to the label in the 2025-08 revision); Maintena instead manages known CYP2D6 poor metabolizers with a reduced dose (300 mg, or 200 mg if also on a strong CYP3A4 inhibitor) rather than an outright contraindication — this is a genuine, verified difference between the two products' current Health Canada labelling, not an inconsistency to be smoothed over.
  • Neither product is contraindicated by age alone, but neither is approved/indicated for dementia-related psychosis in elderly patients (see Geriatrics and Serious side effects).

Drug interactions

Clinically relevant combinations

  • Strong CYP2D6 inhibitors (quinidine, fluoxetine, paroxetine, bupropion) — quinidine increased oral aripiprazole AUC by 107% in studies; for Maintena this requires a dose reduction per the adjustment table; for Asimtufii, concomitant use of strong CYP2D6 inhibitors should be avoided outright (and is an outright avoid-use combination in CYP2D6 poor metabolizers).
  • Strong CYP3A4 inhibitors (ketoconazole, itraconazole, HIV protease inhibitors) — ketoconazole increased oral aripiprazole AUC by 63% and Cmax by 37% in studies; both products require dose reduction per their respective adjustment tables, with the Maintena/Asimtufii dose increased back to the prior level if the inhibitor is later withdrawn.
  • Weak CYP3A4 or CYP2D6 inhibitors (e.g., diltiazem, escitalopram) — may cause modest increases in plasma aripiprazole concentration; no formal dose adjustment table applies, but clinical awareness is warranted.
  • CYP3A4 inducers (carbamazepine, rifampicin, rifabutin, phenytoin, phenobarbital, primidone, efavirenz, nevirapine, St. John's Wort) — carbamazepine lowered oral aripiprazole AUC by about 73% in studies; concomitant use of CYP3A4 inducers with either product for more than 14 days should be avoided because aripiprazole blood levels may fall below effective levels.
  • Antihypertensive agents — because of its α1-adrenergic antagonism, aripiprazole may enhance the effect of certain antihypertensive agents.
  • Alcohol and other CNS-depressant drugs — combination use should be avoided given aripiprazole's primary CNS effects and the risk of overlapping sedative effects; medicines known to prolong the QT interval or cause electrolyte imbalance should also be used cautiously in combination.
  • Aripiprazole itself is not expected to meaningfully affect other drugs: oral doses of 10–30 mg/day had no significant effect on CYP2D6, 2C9, 2C19, or 3A4 substrate metabolism in studies, and no dosage adjustment of dextromethorphan, warfarin, omeprazole, escitalopram, or venlafaxine is required when co-administered.

Food interactions

Meal-related administration

  • Interactions with food have not been established for either product, and neither product's non-medicinal ingredient list nor its Health Canada monograph identifies a specific food-based precaution; this is consistent with aripiprazole's non-oral route of administration for these formulations.

Time of administration

Practical scheduling

  • Neither product is patient-timed the way an oral daily dose would be — both are scheduled healthcare-professional-administered injections rather than something the patient takes at a particular time of day.
  • Maintena is given once monthly, no sooner than 26 days after the previous injection; Asimtufii is given once every two months, no sooner than 56 days after the previous injection, with a permitted administration window of up to 1 week before or after the scheduled two-month timepoint.
  • Because there is no oral dosing-time consideration (food, fasting, morning vs. evening), the only "timing" that matters clinically is keeping to the minimum inter-injection interval and, at initiation, completing the required days of concurrent oral aripiprazole exactly as prescribed (see Dosage & Administration).

Storage

Product handling

  • Abilify Maintena dual-chamber syringe: store between 15°C and 30°C; do not freeze; protect the syringe from light by keeping it in its original package until time of use. Inject immediately after reconstitution.
  • Abilify Maintena vial: store between 15°C and 30°C; inject immediately after reconstitution.
  • Abilify Asimtufii pre-filled syringe: store between 15°C and 30°C. Any unused product or waste material for either product should be disposed of in accordance with local requirements, and sharps (needles/syringes) go into an approved sharps container immediately after use — the used syringe and any unused needle should never be saved for reuse.

Patient take-away

Key counselling points for a quick closing summary

  • These are long-acting injectable forms of aripiprazole given by a healthcare professional — Maintena once a month, Asimtufii once every two months — not pills the patient takes at home; missing an appointment is a clinical issue that needs prompt follow-up, not something to "make up" on your own.
  • When starting either product for the first time, oral aripiprazole (or, if switching from another antipsychotic, that current oral medication) must be continued for 14 days after the first injection — skipping those oral doses can let antipsychotic blood levels drop before the injection has taken full effect.
  • Tell your prescriber and pharmacist right away about any new or unusually strong urges to gamble, shop, eat, or engage in sexual activity that feel hard to control — this is a genuine, documented side effect of aripiprazole specifically (not just "stress"), and it can be managed with a dose reduction or a change in treatment.
  • Watch for and report signs of serious reactions promptly: high fever with severe muscle stiffness and confusion (possible NMS), uncontrollable new movements of the face or body (possible tardive dyskinesia), severe rash with fever or peeling skin, unusual bruising/infection signs (possible low white blood cell count), leg swelling/chest pain/shortness of breath (possible blood clot), or fainting/severe dizziness on standing.
  • Asimtufii is injected only into the buttock (gluteal) muscle, while Maintena may be given in either the buttock or the upper arm (deltoid) — this is a genuine formulation difference, not a scheduling error, and the injection site does not need to alternate between the two drugs.

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.